Novartis AG (NVS)
| Market Cap | 265.01B +28.8% |
| Revenue (ttm) | 56.58B +6.3% |
| Net Income | 13.53B +5.2% |
| EPS | 6.98 +9.5% |
| Shares Out | 1.91B |
| PE Ratio | 19.58 |
| Forward PE | 15.47 |
| Dividend | $3.08 (2.11%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 1,792,228 |
| Open | 146.92 |
| Previous Close | 150.17 |
| Day's Range | 144.72 - 147.50 |
| 52-Week Range | 112.34 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 153.87 (+5.47%) |
| Earnings Date | Jul 16, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $153.87, which is an increase of 5.47% from the latest price.
News
Positive Long-Term Results for Scemblix in CML Trials (NVS)
Positive Long-Term Results for Scemblix in CML Trials (NVS)
Novartis announces 144-week data from ASC4FIRST trial of Scemblix
Novartis (NVS) announced positive 144-week data from the ASC4FIRST trial of Scemblix presented at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. These results provide longer-ter...
Novartis Pluvicto And Actinium Program Advance Radioligand Therapy In Prostate Cancer
(RTTNews) - Novartis AG (NVS) presented new subgroup analyses from its pivotal PSMAddition Phase 3 trial, showing that Pluvicto (lutetium Lu 177 vipivotide tetraxetan) plus standard of care (SoC) cons...
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Basel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on Ju...
Novartis (NVS) Shows Promising Results in Prostate Cancer Treatment
Novartis (NVS) Shows Promising Results in Prostate Cancer Treatment
Novartis announces results on rPFS improvements across subgroups with Pluvicto
Novartis (NVS) announced results showing consistent radiographic progression-free survival, rPFS, improvement across key subgroups with Pluvicto plus standard of care compared to SoC alone in PSMA-pos...
Experimental Novartis radiopharma drug shows promise in early study
Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older...
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Basel, May 31, 2026 – Novartis today announced results showing consistent radiographic progression-free survival (rPFS) improvement across key subgroups with Pluvicto™ (lutetium Lu 177 vipivotide tetr...
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year's European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforce ...
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European ...
US Supreme Court rebuffs pharma challenge to Biden-era drug price
The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that...
Novartis' Pluvicto Shows Lower Risk Of PSA Progression In Phase 3 PSMAddition Trial For MHSPC
(RTTNews) - Novartis (NVS) announced new data from the Phase III PSMAddition trial demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto combined with standard of care (SoC) i...
Novartis (NVS) Reports Promising Data on Pluvicto for Prostate Cancer
Novartis (NVS) Reports Promising Data on Pluvicto for Prostate Cancer
Novartis announces new data from PSMAddition
Novartis (NVS) announced new data from PSMAddition demonstrating improved prostate-specific antigen, PSA, responses with Pluvicto combined with standard of care, SoC, in PSMA-positive metastatic hormo...
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combin...
Health Rounds: Common ADHD medicines help treat cancer-related fatigue
We also report on findings that help explain why the flu can be particularly dangerous for pregnant women and that open the door to potential future treatments.
AVDE, SHEL, HSBC, NVS: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Avantis International Equity ETF (Symbol: AVDE) where we have detected...
Novartis seeks to deepen India innovation play
Swiss pharma major Novartis is sharpening its strategy in India as a pure-play innovator across core therapy segments, including cardiovascular, oncology, and immunology. The company is moving further...
Novartis breaks ground on radioligand therapy manufacturing site in Texas
Novartis (NVS) broke ground on its new 46,000 sq. ft radioligand therapy manufacturing site in Denton, Texas, the latest milestone in its broader $23B investment in U.S. manufacturing and research.
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest mile...
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
Novartis to cut 220 jobs as it closes German site
Swiss drugmaker Novartis said on Tuesday that it is set to cut around 220 jobs in Germany as part of the planned closure of a production site by the end of 2028.
‘I’d lost my identity.’ How this exec recovered from redundancy
A new coach, hypnotist and Hollywood movie helped Allison Rossiter tackle one of her biggest fears. Now, the Novartis president shares how they can help you too.
November 20th Options Now Available For Novartis (NVS)
Investors in Novartis (Symbol: NVS) saw new options become available today, for the November 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the t...
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100